GL1X · GenesisL1 explorer

MolNFT v1 · #49360 · protein

Crystal structure of src kinase domain with covalent inhibitor RL3

2QLQ · Proto-oncogene tyrosine-protein kinase src: “Crystal structure of src kinase domain with covalent inhibitor RL3”. X-ray diffraction, 1 ligand (SR2), 4 pockets (best druggability 0.69). MolNFT v1 #49360 on GenesisL1: 3D structure…

PDB
2QLQ
Type
protein
Length
493 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Proto-oncogene tyrosine-protein kinase src
EC
2.7.10.2
UniProt
P00523
Ligands
SR2
Pockets
4 · best druggability 0.69

Structure

x-ray diffraction · 2 distinct chains · 39% helix, 17% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
AProto-oncogene tyrosine-protein kinase src (EC 2.7.10.2)protein24541% helix, 16% strandP00523
BProto-oncogene tyrosine-protein kinase src (EC 2.7.10.2)protein24838% helix, 18% strandP00523

Ligands and binding sites

  • SR2 · (2E)-N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide · ligand · 3 copies · chains A, B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

4 pockets found on a 1 Å grid, 3 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
16370.690.7771SR2
23630.600.7745empty
33400.590.7739SR2
4770.300.7312empty

Interfaces

1 interface between chains.

  • A–B · 408 Ų buried · 5 hydrogen bonds · protein-protein

Modifications

Observed in the structure: 3 covalent (covalent ligand).

Compared structures

  • 2QLQ · Crystal structure of SRC kinase domain with covalent inhibitor RL3 · the same entry in another collection · chain B against B, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.